PLK1 and cancer: In addition, inhibition of Plk1 in multiple animal models and clinical trials revealed Plk1 as valuable target for cancer therapy (35–38), with a first clinical study to indicate comparable anti-tumor activities of the small molecule Plk1 inhibitor Volasertib (BI6727) and single agent paclitaxel in advanced OC (39).